Navigation Links
Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
Date:10/28/2008

- Presentation to Be Webcast Live On Company's Website -

TUSTIN, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that senior management will present at the BIO Investor Forum 2008 on Thursday, October 30, 2008 at 3:45 pm PDT (6:45 pm EDT). The conference will be held at the Palace Hotel in San Francisco.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at http://www.peregrineinc.com.

For more information about this conference, please visit: http://investorforum.bio.org/opencms/bif/2008/

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio- manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
2. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
5. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
6. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
7. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
8. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
9. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
10. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
11. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
Breaking Biology News(10 mins):